PCSA
Processa Pharmaceuticals, Inc.
Key Financials
Revenue
$0
NaN%
Gross Profit
$5000
↑ 140.2%
Operating Income
$-13988505
↓ 16.1%
Net Income
$-13563834
↓ 14.5%
EPS (Diluted)
$-10.36
↓ 167.7%
Total Liabilities
$2.2M
↑ 45.9%
Total Assets
$7.8M
↑ 142.0%
Shareholders' Equity
$5.6M
↑ 228.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 10/9/2026 | View on SEC |
| PRE 14A | 10/9/2026 | View on SEC |
| S-3 | 10/9/2026 | View on SEC |
| 8-K/A | 10/5/2026 | View on SEC |
| SCHEDULE 13G | 8/18/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 4 | 8/11/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 4 | 7/30/2026 | View on SEC |
| 3 | 7/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PCSA |
| Company Name | Processa Pharmaceuticals, Inc. |
| CIK | 1533743 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 443-776-3133 |